Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Neoplasm Metastasis 1Glioblastoma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Cancer 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
ralimetinib × Clear all
NCT01393990 2020-03-24

A Study of LY2228820 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
89 enrolled 30 charts

Advanced Cancer

NCT01663857 2019-09-11

A Study LY2228820 for Recurrent Ovarian Cancer

Eli Lilly and Company

Phase 1/2 Completed
118 enrolled 18 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT02364206 2019-08-14

GLYRad

Centre Jean Perrin

Phase 1/2 Completed
18 enrolled
CNS

Glioblastoma

NCT02860780 2018-12-14

A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

Eli Lilly and Company

Phase 1 Completed
9 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT02322853 2017-05-24

OLYMPE

Centre Francois Baclesse

Phase 2 Terminated
8 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡